NASDAQ:GPCR Structure Therapeutics Q1 2026 Earnings Report $39.19 +0.40 (+1.03%) Closing price 04:00 PM EasternExtended Trading$38.34 -0.85 (-2.17%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Structure Therapeutics EPS ResultsActual EPS-$0.35Consensus EPS -$0.39Beat/MissBeat by +$0.04One Year Ago EPSN/AStructure Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$11.11 millionBeat/MissN/AYoY Revenue GrowthN/AStructure Therapeutics Announcement DetailsQuarterQ1 2026Date5/7/2026TimeAfter Market ClosesConference Call DateThursday, May 7, 2026Conference Call Time4:00PM ETUpcoming EarningsStructure Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Structure Therapeutics Earnings HeadlinesThis Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 MillionMay 17, 2026 | fool.comStructure Therapeutics (NASDAQ:GPCR) Lowered to Sell Rating by Wall Street ZenMay 16, 2026 | americanbankingnews.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 22 at 1:00 AM | Porter & Company (Ad)Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026 | globenewswire.comWhy Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA PlansMay 3, 2026 | finance.yahoo.comHere is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look atMay 1, 2026 | finance.yahoo.comSee More Structure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Structure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Structure Therapeutics and other key companies, straight to your email. Email Address About Structure TherapeuticsStructure Therapeutics (NASDAQ:GPCR) (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders. The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development. These programs are directed at GPCR targets implicated in diseases such as nonalcoholic steatohepatitis (NASH), fibrosis and immune‐mediated inflammatory conditions. By applying structure‐guided optimization and high‐throughput screening, Structure Therapeutics aims to generate drug candidates with improved selectivity, potency and safety profiles compared with existing modalities. Founded in 2018, the company initially operated under the name GPCR Therapeutics before rebranding as Structure Therapeutics in 2023 to reflect its emphasis on structure‐based drug design. Headquartered in Boston, Massachusetts, Structure Therapeutics collaborates with academic centers, contract research organizations and strategic partners to advance its research and development programs. Its integrated approach combines in silico modeling, biophysical assays and in vivo validation to streamline candidate progression toward human trials. Led by a management team with extensive experience in drug discovery, translational research and clinical development, Structure Therapeutics aims to address areas of high unmet medical need. The company’s scientific leadership includes experts in GPCR biology, structural biology and pharmacology, positioning it to capitalize on breakthroughs in receptor structure elucidation and computational methods. Through its novel platform and focused pipeline, Structure Therapeutics seeks to bring first‐in‐class or best‐in‐class therapies to patients worldwide. View Structure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay BullishTarget Shows Strengths, But Analysts Want to See MoreLowe's Finds Support at $215 After Q1 Earnings Sell-Off Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
